Cardiovascular comorbidity in patients with nonalcoholic fatty liver disease

Ledovskaya TI1, Statsenko ME2, Turkina SV2, Konyakhina TA1, Yusupov KS1, Gorbacheva EE1,2
About authors

1 Volgograd Medical Clinical Center of FMBA, Volgograd, Russia

2 Volgograd State Medical University, Volgograd, Russia

Correspondence should be addressed: Elena E. Gorbacheva
Kim, d. 24, k. 125, Volgograd, 400001, Russia; ur.xednay@1ilsak

About paper

Author contribution: Ledovskaya TI — conceived the idea, performed data analysis and interpretation; Statsenko ME, Turkina SV — formulated the problem and organized the study; Konyakhina TA — performed literature analysis and research conceptualization; Yusupov KS — searched the literature and wrote the manuscript; Gorbacheva EE — performed data analysis and interpretation.

Received: 2021-12-07 Accepted: 2021-12-20 Published online: 2021-12-22

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide. It is characterized by hepatic steatosis and stetohepatitis and in some cases can progress to cirrhosis with or without hepatic failure and hepatocellular carcinoma. At present, NAFLD is deemed a predictor of cardiovascular risk. Besides, it can aggravate pre-existing cardiovascular conditions. Structural and functional changes in the heart, liver and blood vessels are interdependent and mutually aggravating. Metabolic factors (dyslipidemia, hyperglycemia and insulin resistance) contribute to hepatic, cardiac and vascular damage, and NAFLD and comorbid cardiovascular disorders together can activate fibrogenesis in the heart, blood vessels and liver.

Keywords: endothelial dysfunction, nonalcoholic fatty liver disease, fatty steatosis, nonalcoholic steatohepatitis, liver fibrosis